03:45 PM EST - Aeterna Zentaris Inc. : announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108. Aeterna Zentaris Inc.
shares T.AEZ are trading up $0.05 at $1.74.
